FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.
What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.
Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.
Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma
Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or […]
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.
Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?
Senhwa Biosciences Inc. and BeOne Medicines have signed a clinical supply agreement to explore a novel drug combination aimed at treating hard-to-reach cancers. The collaboration will test Senhwa’s lead compound Pidnarulex (CX-5461), a G-quadruplex stabilizer, in combination with BeOne’s PD-1 inhibitor tislelizumab. The Phase 1b/2a clinical trial will enroll patients with advanced solid tumors, including […]
Can Akeso’s cadonilimab unlock PD-L1-agnostic immunotherapy for gastric cancer patients?
Akeso Inc. has secured clearance from the United States Food and Drug Administration to initiate COMPASSION-37, a global Phase III trial evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, as part of a first-line treatment regimen for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. The randomized, multicenter trial will compare cadonilimab plus chemotherapy against […]